After publication of our recent article [1], we noticed an error in the unit for the area under the time-concentration curve between 0 and 12 hours (AUC0-12 h). Throughout the article and Table 1 the unit should be mg·h/L (mg multiplied by hour per L) not mg/hour/L.
Table 1.
Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical outcome (univariate analysis)
| Total | Successes | Failures | ||
|---|---|---|---|---|
| Inclusion characteristic | n = 26 | n = 17 | n = 8 | P valuea |
| Demographic | ||||
| Females/Males, number | 16/10 | 12/5 | 4/4 | 0.28b |
| Age, years | 46 (35-61)a | 46.5 (35-61) | 46 (38-61) | 0.9 |
| Body weight, kg | 60 (56-75) | 60 (56-75) | 62 (58-82.5) | 0.62 |
| Disease | ||||
| Duration before entry, months | 11 (7-14) | 11 (7-12) | 10 (6-13) | 0.30 |
| SLEDAI score | 0 (0-2) | 0 (0-2) | 0 (0-2) | 0.20 |
| C3, g/L | 1 (0.6-1.1) | 1 (0.9-1.1) | 0.8 (0.56-0.96) | 0.21 |
| C4, g/L | 0.2 (0.1-0.2) | 0.2 (0.1-0.2) | 0.2 (0.16-0.24) | 0.78 |
| Anti-double-stranded DNA, IU/mL | 24 (6-51) | 8 (1-32) | 38 (9-55) | 0.19 |
| Biological | ||||
| GFR, mL/minute | 95 (67-125) | 95 (67-125) | 93.5 (76-109) | 0.64 |
| Albumin, g/L | 40 (39.8-43.8) | 40 (37.9-43.8) | 42.8 (40-46.9) | 0.33 |
| Aspartate aminotransferase, IU/L | 23 (19-26) | 23 (17.5-24.5) | 28 (20-33) | 0.26 |
| Alanine aminotransferase, IU/L | 22 (15-29) | 19 (13-24.5) | 25 (19-37) | 0.21 |
| γ-Glutamyltransferase, IU/L | 24 (17-63) | 23 (17-21) | 42 (17-61) | 0.92 |
| Treatment | ||||
| MMF, g/day | 2 (2-2) | 2 (2-2) | 2 (2-2) | 0.9 |
| Corticosteroids, mg/day | 11 (7-35) | 10 (5-20) | 15 (7-45) | 0.37 |
| Months of MMF therapy | 2 (1-3) | 2 (1-3) | 2 (1-3) | 0.56 |
| Months of corticosteroids | 10 (6-13) | 10 (5-15) | 9 (5-14) | 0.12 |
| MPA pharmacokinetic parameters | ||||
| AUC0-12 h' mg·hour/L | 64.7 (38.2-82) | 73.1 (61.8-95) | 37.7 (32-43.7) | 0.003 |
| Cmax' mg/L | 16.1 (9.5-18.5) | 16.3 (9.7-17.4) | 13.3 (7-22.5) | 0.69 |
| Tmax' hours | 1 (1-2) | 1 (1-2) | 1.1 (1-2) | 0.82 |
| C12 h' mg/L | 2.4 (1.5-4.1) | 3.7 (2.3-4.9) | 1.5 (0.6-2.1) | 0.008 |
| MPAG pharmacokinetic parameters | ||||
| AUC0-12 h' mg·hour/L | 775.3 (475-1,026) | 791 (635-1,166) | 678.8 (426-840.6) | 0.22 |
| Tmax' hours | 2 (2-3) | 2.3 (2-3) | 1.3 (1-2) | 0.01 |
| C12 h' mg/L | 32.1 (24.3-41.9) | 34.7 (26.4-49.2) | 29.8 (15.5-40) | 0.26 |
| MPAG/MPA AUC0-12 h ratio | 11.5 (8.3-20.7) | 10.9 (6.2-14.8) | 18.7 (14.1-22.7) | 0.07 |
| MPAG/MPA C12 h ratio | 11.5 (6.8-17.3) | 10.2 (6.3-15) | 18.7 (11.5-47.2) | 0.02 |
Values are expressed as median (interquartile range) unless stated otherwise. aMann-Whitney U test; bFisher exact test. AUC0-12 h' area under the plasma concentration-versus-time curves for hours 0 to 12; C12 h' 12-hour trough concentration; Cmax' maximal concentration; GFR, glomerular filtration rate (estimated with the Cockcroft-Gault formula); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; Tmax' time to maximal concentration.
The correct table is given here as Table 1.
Competing interests
The authors declare that they have no competing interests.
See related research article by Djabarouti et al., http://arthritis-research.com/content/12/6/R217
References
- Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. Arthritis Res Ther. 2010;12:R217. doi: 10.1186/ar3202. [DOI] [PMC free article] [PubMed] [Google Scholar]